◈ Nootpedia
Compact view
Research pass: medium SARM · Oral SKIP-FOR-NOW HIGH

Ostarine

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

At 20yo with peak natural HPG axis, AR-axis modulation is gratuitous; ostarine's documented HPG suppression (less than LGD-4033 but still real and dose-dependent), unresolved hepatotoxicity case-report signal, and complete absence of long-term safety data in young eugonadal men make this a textbook risk-stack-without-need scenario. Combined with research-chem-only sourcing (FDA-prohibited supplement channel + counterfeit/contamination-prone gray market), the appropriate verdict is firm SKIP. Verdict would not change pre-25 absent unforeseen indication; would re-evaluate post-25 only with documented anabolic-deficient state and validated pharmaceutical-grade source.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, peak natural HPG axis (Dylan-archetype)
    SKIP-AT-

    No indication, no documented anabolic deficit, real HPG suppression, hepatotoxicity case-report tail risk, FDA-prohibited supply chain with high mislabeling rate. Same logic as LGD-4033. Creatine + sleep + protein + training delivers similar/better LBM gains over equivalent timelines without any of the downsides.

  • 20-30, dedicated competitive lifter, untested division, accepts research-chem risk
    SKIP-FOR-NOW

    as default; informed-user STRONG-CANDIDATE only with bloodwork-monitored cycling, pharmaceutical-grade source, and clear training context. Even then, gain is modest vs. risk.

  • 30-50, executive maintenance, normal T
    SKIP

    no indication.

  • 30-50, age-related sarcopenia, low-normal T, high anabolic demand
    WATCH-LIST

    Veru's clinical program may produce pharmaceutical-grade supply for this niche; until then, research-chem risk dominates.

  • 50+, sarcopenia, especially during GLP-1-induced weight loss
    WATCH-LIST

    → STRONG-CANDIDATE if FDA-approved via Veru pathway. This is the genuine clinical use case ostarine may eventually serve. Outside trials, research-chem risk still rules out.

  • Cancer cachexia (NSCLC, advanced cancer)
    NOT

    FDA-APPROVED, FAILED PHASE 3. Investigational only.

  • Breast cancer (AR+/ER+ post-AI)
    INVESTIGATIONAL

    Veru's current Phase 3 program. Not for off-label use.

  • Anxiety-prone
    M

    N/A — ostarine is not psychoactive in either direction. PCT-recovery mood drop is the main anxiety-relevant period.

  • Tested athlete (WADA, USADA, NCAA, professional combat sport)
    SKIP-PERMANENT

    S1.2 banned, multi-week detection window, contamination risk creates false-positive pathway even from "clean" supplements.

  • DylanHigh athletic load, untested status (Dylan's combat-sport profile)
    SKIP-AT-

    same as primary archetype. Combat sport's high training load + injury risk does not invert the calculus; there's no SARM-specific recovery edge that peptides + standard recovery don't deliver more cleanly.

  • Sleep-disordered
    A

    sleep first.

  • Recovery-focused (post-injury, post-illness)
    WEAK

    CANDIDATE at best. BPC-157, TB-500, sleep, protein, vitamin D, and time deliver better evidence-based recovery without HPG hit.

  • Strength/anabolic-focused, non-competitive, accepts gray-market risk
    OPTIONAL-ADD

    with strict caveats — bloodwork pre/during/post, COA-verified source, ≤25mg/day, ≤12 weeks, full PCT plan. Even informed user should weigh against creatine + nutrition + training as a higher floor.

  • Post-AAS-cycle bridge
    U

    in PED community for "bridging" between AAS cycles to maintain LBM at lower suppression — outside scope here, AAS-cycling not Dylan's profile.

▸ Subjective experience (deep)

Ostarine is widely described in user reports as "the mildest SARM" — usually no acute felt effect, no euphoria, no aggression. Effects compound across weeks 3-12:

  • Week 1-2: Nothing perceptible most days; occasional users report mild appetite increase, slightly improved gym recovery, joint comfort.
  • Week 3-6: Recovery between training sessions feels noticeably better; lean mass starts visibly accumulating; pump/fullness in muscles increases (likely glycogen + minor true LBM); strength gains modest.
  • Week 6-12: ~3-6 lbs LBM, ~5-10% strength gains on compound lifts at moderate doses (15-25mg/day). Joint comfort often cited (likely real — ostarine is studied for osteoporosis and chondral effects).
  • Post-cycle: Lean mass partially retained (60-80% in compliant users with continued training) but strength rebound varies; energy, libido, and morning erections may dip mildly during PCT recovery.

Vs. testosterone or LGD-4033: Substantially milder. Users describe ostarine as "barely noticeable but works" — opposite of trenbolone's high-feel/high-impact profile. This mildness is also why side effects can sneak up on users (low felt warning before LFT or lipid derangement).

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Modest receptor downregulation reported with extended use; most users do not escalate dose meaningfully within an 8-12 week cycle. Re-cycling shows similar response to first cycle in most reports.
  • Recommended cycle (community convention): 8-12 weeks on, 4-8 weeks off (often with mini-PCT). Continuous use beyond 12-16 weeks substantially increases liver and HPG concerns without clear additional gain.
  • Reset protocol if needed: Discontinue. PCT (clomiphene 25mg/day or nolvadex 20mg/day × 4 weeks) for users with substantial suppression. Bloodwork at week 6 post-cycle to confirm recovery.
▸ Stacking deep dive

Synergistic with

  • (For an athlete who shouldn't be on this in the first place, "synergy" framing is misleading — but for completeness in case of future re-evaluation in different demographic context:)
  • Creatine — independent additive lean-mass effect, no pharmacological collision. A-tier rationale.
  • Adequate protein (≥1.6 g/kg) — substrate for any anabolic stimulus. A-tier.
  • Vitamin D + zinc + magnesium (Dylan's V4 already) — supports endogenous T axis during PCT recovery.

Avoid stacking with

  • LGD-4033, RAD-140, other SARMs: Compounds suppression, no proven additive efficacy. Common community mistake.
  • AAS (testosterone, trenbolone, anavar, etc.): Defeats the "milder than AAS" pitch; combines suppression and toxicity profiles.
  • 17α-alkylated oral AAS (oxandrolone, methyltestosterone, stanozolol, oxymetholone): Liver-load stacking — ostarine's idiosyncratic hepatotoxicity plus 17α-alkyl liver strain is a known bad combination.
  • Hepatotoxic medications or supplements (acetaminophen ≥3g/day chronic, isoniazid, methotrexate, high-dose niacin, etc.).
  • Heavy alcohol: Liver-load compounding.
  • Other research-chem compounds with unknown contamination profiles — multiplies counterfeit risk.

Neutral / safe co-administration

  • Most non-hormonal nootropics in Dylan's V4: modafinil, citicoline, NAC (NAC is hepatoprotective — mild positive), magnesium, fish oil, theanine, rhodiola, curcumin, beta-alanine, creatine. No documented hormone-axis collisions.
  • Caffeine — no interaction.
▸ Drug interactions deep dive
  • CYP3A4 substrate: Inducers (rifampin, carbamazepine, St. John's Wort) reduce ostarine exposure; inhibitors (azole antifungals, macrolides, grapefruit) elevate it — clinically uncharacterized but theoretically meaningful.
  • NAC / glutathione precursors: Mild hepatoprotection (already in Dylan's stack at 1200 mg/day).
  • Statins: No documented direct interaction; both potentially impact LFTs additively.
  • Hormonal contraceptives (relevant for female users): SARMs disrupt menstrual cycle and contraceptive efficacy unpredictable; not Dylan-relevant.
  • Anti-doping: WADA S1.2 (Other Anabolic Agents) — full ban, in- and out-of-competition. Detection window 6-9+ weeks post-cessation.
▸ Pharmacogenomics
  • CYP3A4 polymorphisms: Affect ostarine metabolism rate; no validated clinical pharmacogenomics for SARM dosing.
  • AR CAG repeat length: Shorter CAG (<22 repeats) correlates with higher AR transactivation efficiency and may modulate SARM response magnitude — unstudied for ostarine specifically.
  • UGT2B17 deletion: Affects testosterone glucuronidation and the urinary T/E ratio used in WADA testing — relevant for false-positive risk assessment, not ostarine pharmacology.
  • Practical: No genotype currently used to dose SARMs clinically.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx None N/A N/A Not FDA-approved. No legal pharmaceutical source in the US. Veru's investigational supply is trial-only.
FDA-prohibited "supplement" channel Various pre-2017 brands N/A very low FDA issued warning letters in 2017; products containing ostarine in dietary supplements are illegal. Many continue to operate. JAMA 2017 found 52% label accuracy across SARM products tested.
Research-chem vendor Chemyo, Science.bio (defunct), Sports Technology Labs, Behemoth Labz, etc. $30-60 / 30 mL @ 25 mg/mL low-medium "For research purposes only" labeling. COA quality varies vendor to vendor; some publish independent third-party assays, most don't. Adulteration / mislabeling rate ~30-50% in independent JAMA + Cohen testing. Dylan's COA-verification standard is necessary but does not eliminate batch-variance risk.
International / Indian / Chinese pharmacy Various $30-100 / cycle low API quality varies; counterfeit risk; legality murky outside source country.

FDA status (current): Prohibited in dietary supplements (FDA warning, 2017; consumer advisory reaffirmed 2024). Possession for personal "research" exists in legal gray zone — not scheduled by DEA, but selling for human consumption is FDA-actionable. Dylan's research-chem comfort applies, but the underlying product reliability is among the worst in the supplements/research-chem ecosystem.

▸ Biomarkers to track (deep)
  • Baseline (before starting): Total testosterone (LC-MS/MS), free T, SHBG, LH, FSH, sensitive E2, prolactin, lipid panel (HDL especially), CMP w/ LFTs (ALT, AST, GGT, alk phos, total bilirubin), CBC w/ hematocrit, PSA (if >40), 25(OH)D, ferritin, creatinine. For Dylan: this is the June 2026 panel regardless — no ostarine-specific addition needed because he won't be on it.
  • During use (if hypothetically used): LFTs at 4 and 8 weeks (highest risk window for hepatotoxicity onset), lipid panel at 6 weeks, total T + LH + FSH + E2 at week 8 to assess suppression, hematocrit. Symptom diary (jaundice/pruritus/dark urine warning signs, libido, mood, energy).
  • Post-cycle: Total T, LH, FSH at 2, 4, 6 weeks post to confirm axis recovery. LFTs to confirm normalization. Lipid panel to confirm HDL recovery.
▸ Controversies / open debates Live debate

1. "SARMs are non-suppressive" claim (forum folklore)

The claim: "Ostarine doesn't suppress like AAS — that's the whole point of SARMs."

Reality: Ostarine is less suppressive than testosterone or LGD-4033 at equimolar AR occupancy. But less ≠ none. Phase 1/2 data and community bloodwork consistently show 25-40% T drops at 3 mg/day cachexia dose, and proportionally more at the 15-25 mg/day bodybuilding doses. PCT is genuinely needed for many users at typical bodybuilding doses, and the "no PCT needed" forum advice has produced documented cases of prolonged hypogonadism. The non-suppressive framing is wrong as commonly stated.

2. Hepatotoxicity — true incidence vs. case-report bias

The case-report literature is unambiguous that ostarine can cause cholestatic hepatitis in young men at ostensibly modest doses. What's unclear is the population incidence — case reports are biased toward severe presentations requiring medical attention, and the underlying user base is unmeasured (research-chem use is by definition unsurveilled). Estimates of "1 in 1000" or "1 in 100" are not data-grounded. The honest claim is: incidence is unknown, but the mechanism appears idiosyncratic, severity ranges from mild ALT bump to transplant evaluation, and recovery on cessation is usually but not always complete. That's enough signal to treat seriously.

3. Veru's relaunch — will enobosarm get FDA-approved?

Veru Inc. acquired the enobosarm IP after GTx wound down and is running multiple programs:

  • AR+/ER+ breast cancer post-AI (ENABLAR-2): Phase 3 ongoing.
  • GLP-1-induced sarcopenia (QUALITY, ENHANCE): Phase 2b/3, partial 2024-2025 readouts mixed. Lean mass preservation real; functional and clinical-benefit endpoints uncertain.

If Veru succeeds in either indication, a pharmaceutical-grade supply chain emerges and the clinical-pharmacology / safety dataset expands meaningfully. Until then, research-chem is the only access path. The gap between "FDA-approved enobosarm for sarcopenia in 2027-2030" and "research-chem ostarine in 2026" is a substantial regulatory / quality / liability gap.

4. WADA contamination cases

A meaningful fraction of WADA ostarine positives in tested athletes are attributed to contamination of legal supplements (creatine, pre-workout, protein powders) at sub-therapeutic doses. Athletes who have not knowingly used SARMs have tested positive due to manufacturing-line cross-contamination. For Dylan: untested status makes this irrelevant for sanctioning, but it's a sign of how widespread the supply contamination is.

5. "Healing" use for joints and tendons

Lifter community uses 10-15 mg/day for joint comfort and tendon recovery. AR is expressed in chondrocytes, osteocytes, and tenocytes; partial agonism is mechanistically plausible. But:

  • No human RCT specifically evaluates ostarine for tendonopathy or osteoarthritis.
  • BPC-157 + TB-500 (Dylan's planned elbow protocol) have higher mechanistic specificity for soft-tissue healing without HPG hit.
  • "Healing dose" still produces measurable HPG suppression.

Verdict on healing use: Inferior to peptide alternatives that don't perturb the axis.

6. Prior-verdict revisit

In V5 / encyclopedia, ostarine was lumped into the "SARM family — SKIP-AT-20" verdict alongside LGD-4033 and RAD-140. This file confirms: ostarine is the mildest of the three but qualitatively sits in the same bucket — not a meaningful exception. The mildness argues for less harm if used, not more reason to use. Same skip rationale, same confidence, slightly softer mechanism profile.

▸ Verdict change log
  • 2026-05-04 (Encyclopedia v5) — Listed in SARM family with SKIP-AT-20 LOW-MEDIUM family-level confidence.
  • 2026-05-05 (this file, parallel SARM build) — SKIP-AT-20 HIGH confidence. Verdict-confidence elevated from LOW-MEDIUM (family-tier) to HIGH (compound-specific) after deep research: HPG suppression confirmed real and dose-dependent, hepatotoxicity case-report literature reviewed, FDA-prohibited supply chain documented, Phase 3 cachexia failure confirmed, Veru relaunch context added. Same logic as LGD-4033 but with a slightly different efficacy/risk ratio and the additional liver-injury idiosyncratic signal that LGD-4033 has less of.
▸ Open questions / gaps Open
  • True population incidence of cholestatic hepatotoxicity: Unknown; case-report-based estimates only.
  • Long-term (>1 year) HPG-axis effects of cycled use in young men: Unstudied.
  • Veru's Phase 3 readouts (full data 2026-2027): Will determine if a pharmaceutical-grade enobosarm path emerges.
  • Cardiovascular outcomes from chronic HDL suppression: No MACE data in any SARM population.
  • Pharmacogenomic responder phenotyping (CYP3A4, AR CAG): Plausible candidates, no validated guidance.
  • True post-cycle axis recovery time distribution: Most case series show full recovery in 4-8 weeks, but tail-end users with prolonged recovery exist; predictors are poorly characterized.
  • Soft-tissue healing in well-designed RCT: Doesn't exist for ostarine; community claim is mechanistic plausibility plus anecdote.
▸ Sources (full, with our context)
Back to compact view